302 related articles for article (PubMed ID: 30345704)
21. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.
Heidrich B; Vital M; Plumeier I; Döscher N; Kahl S; Kirschner J; Ziegert S; Solbach P; Lenzen H; Potthoff A; Manns MP; Wedemeyer H; Pieper DH
Liver Int; 2018 Jan; 38(1):50-58. PubMed ID: 28561276
[TBL] [Abstract][Full Text] [Related]
22. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
23. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
Gentile I; Scotto R; Coppola C; Staiano L; Amoruso DC; De Simone T; Portunato F; De Pascalis S; Martini S; Macera M; Viceconte G; Tosone G; Buonomo AR; Borgia G; Coppola N
Hepatol Int; 2019 Jan; 13(1):66-74. PubMed ID: 30523552
[TBL] [Abstract][Full Text] [Related]
24. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
25. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
26. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
[TBL] [Abstract][Full Text] [Related]
27. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
28. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
[TBL] [Abstract][Full Text] [Related]
29. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
[TBL] [Abstract][Full Text] [Related]
30. Gut microbiota changes and chronic hepatitis C virus infection.
Preveden T; Scarpellini E; Milić N; Luzza F; Abenavoli L
Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):813-819. PubMed ID: 28621554
[TBL] [Abstract][Full Text] [Related]
31. Changes in the gut microbiota after hepatitis C virus eradication.
Honda T; Ishigami M; Yamamoto K; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Nakamura M; Kawashima H; Miyahara R; Ishikawa T; Hirooka Y; Fujishiro M
Sci Rep; 2021 Dec; 11(1):23568. PubMed ID: 34876650
[TBL] [Abstract][Full Text] [Related]
32. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
Gorin JB; Malone DFG; Strunz B; Carlsson T; Aleman S; Björkström NK; Falconer K; Sandberg JK
Sci Rep; 2020 Feb; 10(1):2081. PubMed ID: 32034167
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C.
Umemura T; Yamazaki T; Joshita S; Sugiura A; Fujimori N; Matsumoto A; Ota M; Tanaka E
Cytokine; 2018 Nov; 111():357-363. PubMed ID: 30296712
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in Antiviral Therapy for Chronic Hepatitis C.
Tamori A; Enomoto M; Kawada N
Mediators Inflamm; 2016; 2016():6841628. PubMed ID: 27022210
[TBL] [Abstract][Full Text] [Related]
35. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.
Drazilova S; Janicko M; Skladany L; Kristian P; Oltman M; Szantova M; Krkoska D; Mazuchova E; Piesecka L; Vahalova V; Rac M; Schreter I; Virag L; Koller T; Liptakova A; Ondrasova M; Jarcuska P
Can J Gastroenterol Hepatol; 2018; 2018():6095097. PubMed ID: 30402450
[TBL] [Abstract][Full Text] [Related]
36. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
37. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
38. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
Wellhöner F; Döscher N; Tergast TL; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Maasoumy B; Wedemeyer H; Cornberg M; Pieper DH; Heidrich B
Scand J Gastroenterol; 2019 Aug; 54(8):1033-1041. PubMed ID: 31361979
[No Abstract] [Full Text] [Related]
39. Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.
Abdurakhmanov DT; Rozina TP; Nikulkina EN; Nabatchikova EA; Chulanov VP; Moiseev SV
Antivir Ther; 2018; 23(8):705-708. PubMed ID: 30265242
[TBL] [Abstract][Full Text] [Related]
40. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
